SCHEMBL4811883

SCHEMBL4811883

Cl[C@@H]1CCCN(CCc2cccc(N3CCCC3)c2)C1

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 3/20 0.62
L3MBTL1 Q9Y468 3/20 0.62
MBTD1 Q05BQ5 2/20 0.48
TP53BP1 Q12888 2/20 0.48
SIGMAR1 Q99720 3/20 0.46
HRH3 Q9Y5N1 2/20 0.46
SLC6A3 Q01959 2/20 0.46
AGXT P21549 1/20 0.45
PRMT6 Q96LA8 1/20 0.44
DRD2 P14416 3/20 0.43
DRD3 P35462 2/20 0.43
DRD1 P21728 1/20 0.43
DRD4 P21917 1/20 0.43
DRD5 P21918 1/20 0.43
HTR1A P08908 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4811899 1.00 L3MBTL3 (0.62) L3MBTL3L3MBTL1MBTD1TP53BP1SIGMAR1
SCHEMBL4814066 0.84 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1TP53BP1SIGMAR1
SCHEMBL4814084 0.84 L3MBTL3 (0.58) L3MBTL3L3MBTL1MBTD1TP53BP1SIGMAR1
SCHEMBL4808902 0.82 L3MBTL3 (0.72) L3MBTL3L3MBTL1MBTD1TP53BP1SIGMAR1
SCHEMBL7348925 0.81 SLC6A3 (0.61) SIGMAR1SLC6A3DRD2DRD3
SCHEMBL7348929 0.81 SLC6A3 (0.61) SIGMAR1SLC6A3DRD2DRD3
SCHEMBL7355606 0.81 SLC6A3 (0.61) SIGMAR1SLC6A3DRD2DRD3
SCHEMBL4808499 0.81 L3MBTL3 (0.60) L3MBTL3L3MBTL1MBTD1TP53BP1SIGMAR1
SCHEMBL4808485 0.81 L3MBTL3 (0.60) L3MBTL3L3MBTL1MBTD1TP53BP1SIGMAR1
SCHEMBL7359013 0.79 HRH3 (0.69) SIGMAR1HRH3HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7320973-B2 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2008-01-22 US disclosed
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same AJINOMOTO CO., INC. (JP) 2004-06-10 US disclosed
EP-1403258-A1 DIHYDRODIARYLOXAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE DERIVATIVE Ajinomoto Co., Inc. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110742-A1 Dihydrodiaryloxazepine derivative and pharmaceutical composition containing the same CYP3A4, PPARD, CYP4B1 L3MBTL3 4874/4885L3MBTL1 4810/4885MBTD1 2551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.